ASH 2018 | Selinexor brings a STORM for penta-refractory MM
Selinexor targets exportin-1, a novel target for multiple myeloma (MM) therapy. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Keith Stewart, MB, ChB, of the Mayo Clinic, Rochester, MN, discusses the outcomes from the STORM trial (NCT02336815), a pivotal study for penta-refractory MM patients. Dr Stewart mentions that tolerability is an issue to consider, although addition of dexamethasone can aid in the management of this.
Get great new content delivered to your inboxSign up